Previous 10 | Next 10 |
Upfront payments received from licensing deals in South Korea for Piclidenoson and Namodenoson with upfront and milestone payments of up to $10 million plus transfer pricing Preparatory work for an End of Phase II meeting with FDA to initiate Phase III study in liver can...
Community First Bancshares ( CFBI -0.4% ) agrees to buy ABB Financial Group, the parent company of Affinity Bank, in a deal that will expand CFBI's presence in the Atlanta market. More news on: Community First Bancshares, Inc., Financial stocks news, Merger & acquisition news, ...
Community First Bancshares, Inc. (NASDAQ: CFBI) (“CFBI”), the parent company of Newton Federal Bank, and ABB Financial Group, Inc. (“ABB”), parent company of Affinity Bank, announced today that they have entered into a definitive merger agreement whereby CFBI has a...
Drug supply for compassionate use has been manufactured and is ready for use Namodenoson has both Fast Track and Orphan Drug Status with U.S. FDA Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of propriet...
- Up to $4,000,000 in upfront and milestone payments, plus a transfer price for delivering finished product - Piclidenoson is currently in Phase 3 for the treatment of psoriasis Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pi...
Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that the Company’s VP of Business Development, Sari Fishman, is conducting one...
Phase III study protocol for Namodenoson in the treatment of advanced liver cancer patients is now being prepared and will be presented to FDA in an End of Phase II meeting Can-Fite BioPharma Ltd . (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary s...
Preparatory work for an end-of-Phase II FDA meeting to initiate a Phase III study in liver cancer is ongoing Top-line data from Phase II NASH study with Namodenoson expected in H2 2019 Patient enrollment continues in two Phase III studies for Piclidenoson in the treatment...
The podium presentation will be in a session of ‘Selected Abstracts of Excellence’ Top line data from Can-Fite Phase II study of Namodenoson in the treatment of NAFLD and NASH expected H2 2019 Preclinical data show improved liver function, anti-inflammatory,...
PETACH TIKVA, Israel, May 20, 2019 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI) , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it has entered ...
News, Short Squeeze, Breakout and More Instantly...
Community First Bancshares Inc. Company Name:
CFBI Stock Symbol:
NASDAQ Market:
(NewsDirect) Multiple countries are approving Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) ’s Namodenoson for compassionate use in patients with advanced liver cancer. These countries, including Romania and Israel, seem to have acknowledged Namodenoson...
(NewsDirect) The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up. Psoriasis is a chronic inflammatory skin disease caused by genetic disposition or environmental factors and is a burgeoning $16 b...
Community First Bancshares, Inc. (the “Company”), the stock holding company of Newton Federal Bank (the “Bank”), announced today that it has received all required regulatory approvals for the conversion of Community First Bancshares, MHC (the “MHC ...